Pharmafile Logo
Pharmafocus logo
Advanced Search

blood cancer

Showing 15 posts of 32 posts found.

cancer

Genmab’s CLL drug gets negative opinion from EMA committee

June 24, 2016
Medical Communications, Research and Development, Sales and Marketing Arzerra, CHMP, CLL, EMA, Genmab, blood cancer

Genmab A/S (Nasdaq Copenhagen: GEN) said its drug Arzerra (ofatumumab) received a negative opinion by the Committee for Medicinal Products …

News
celgene_1_02

Nice rejects Celgene’s drug to treat blood cancer

June 24, 2016
Medical Communications, Research and Development CDF, Celgene, NICE, Vidaza, blood cancer

The National Institute for Health and Care Excellence (Nice) rejected biotech firm Celgene’s (Nasdaq: CELG) Vidaza (azacitidine) to treat a …

News
janssen_latest_logo_on_sign_closer

Janssen says Imbruvica shows improved PFS in blood cancer in long-term effectiveness study

June 14, 2016
Manufacturing and Production, Research and Development Janssen, blood cancer, drug trial, imbruvica

Janssen said late-stage studies to test long-term effectiveness for its Imbruvica (ibrutinib) in blood cancer showed improved progression free survival …

News
gilead-sciences

EMA starts review of Gilead Sciences’ Zydelig following safety concerns

March 14, 2016
Research and Development, Sales and Marketing EMA, Gilead Sciences, blood cancer, clinical trials, zydelig

Regulators in Europe have initiated a safety review of Gilead Sciences’ (Nasdaq: GILD) blood cancer drug Zydelig (idelalisib) following reports …

News
AZ building

AstraZeneca in $5bn Acerta buyout talks

December 14, 2015
Sales and Marketing Acerta Pharma, AstraZeneca, acalabrutinib, acquisitions, blood cancer, buyout, chronic lymphocytic leukaemia, mergers, takeover

AstraZeneca has confirmed it is in negotiations to buy cancer drug developer Acerta Pharma BV for more than $5 billion …

News
Roche image

Roche falls foul of NICE rules, again

October 3, 2014
Medical Communications, Sales and Marketing CLL, Gazyvaro, NICE, Roche, blood cancer, oncology

Uncertainties in the data and high cost have seen NICE make an initial rejection of Roche’s new blood cancer drug …

News
Zydelig image

Gilead’s blood cancer pill approved in Europe

September 22, 2014
Sales and Marketing CLL, Gilead, blood cancer, fl, idelalisib, oncology, zydelig

Gilead has gained European Commission approval for its new blood cancer pill Zydelig (idelalisib) as it looks to expand further …

News
Infinity image

AbbVie and Infinity sign cancer deal

September 4, 2014
Research and Development, Sales and Marketing AbbVie, IPI-145, blood cancer, duvelisib, infinity

AbbVie has partnered with US company Infinity Pharmaceuticals to develop and commercialise the latter firm’s blood cancer treatment duvelisib (IPI-145). …

News
Arzerra image

EMA gets first line Arzerra submission

October 7, 2013
Sales and Marketing Arzerra, GSK, Genmab, blood cancer

GlaxoSmithKline and Genmab have submitted their blood cancer drug Arzerra to the European Medicines Agency (EMA) in a first line …

News

Ariad files new blood cancer drug with the FDA

July 31, 2012
Research and Development, Sales and Marketing Ariad, CML, EMA, FDA, Glivec, blood cancer

Ariad has filed its investigational blood cancer drug ponatinib with the FDA and hopes for an accelerated review. The US …

News

Blood cancer charity to kick-start clinical trials

May 19, 2011
Research and Development Cancer, blood cancer, clinical trials, leukaemia

A UK blood cancer charity is creating a network of clinical trial centres with backing from the NIHR Clinical Research …

News

Novartis plans Q2 filing for blood cancer drug

March 17, 2011
Sales and Marketing COMFORT-II trial, INC424, Incyte, JAK, Janus kinase inhibitor, Novartis, blood cancer, cancer drug, myelofibrosis, ruxolitinib

Novartis will file ruxolitinib for worldwide regulatory approval in the second quarter after the cancer drug met its primary endpoint …

News

Novartis blood cancer drug impresses in late stage trial

December 22, 2010
Research and Development, Sales and Marketing INC424, Novartis, blood cancer, myelofibrosis, orphan drug

Novartis has released positive phase III results of its myelofibrosis drug INC424 showing it met its primary endpoint of reducing …

News

Roche’s MabThera successor shows phase II promise

December 6, 2010
Research and Development, Sales and Marketing GA101, Genentech, GlycArt, MabThera, Roche, blood cancer, chronic lymphocytic leukaemia

The cancer drug Roche is developing as a second-generation successor to its blockbuster MabThera has shown promising results in a …

News

Pfizer withdraws blood cancer drug in US

June 22, 2010
Sales and Marketing AML, Mylotarg, Pfizer, blood cancer

The US regulatory body has withdrawn Pfizer’s leukaemia drug Mylotarg after it was linked to a number of deaths, and …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025